Reyataz label
Interaction Color Code
Clinical Bottom Line
Do not coadminister: Reduced levels of atazanavir and increased levels of etravirine
Drug 1
Drug 1 dose
400 mg daily
Drug 1 effect
Atazanavir AUC decreased 17%, Cmin decreased 47%
Drug 2
Drug 2 effect
Etravirine AUC increased 50%, Cmax increased 47%, Cmin increased 58%
Clinical Effects
Potential increased etravirine effects, decreased atazanavir effects
Management
Use alternative agents
Import ID
841
